The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Xywav
calcium, magnesium, potassium, and sodium oxybates · SODIUM OXYBATE .5 g/mL; CALCIUM OXYBATE .5 g/mL; POTASSIUM OXYBATE .5 g/mL; MAGNESIUM OXYBATE .5 g/mL · Solution · Oral · Jazz Pharmaceuticals, Inc.
NDC 68727-0150-01 · 180 mL in 1 BOTTLE, PLASTIC · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$37.03per dosage unitgross, before rebates — matched by drug name · 2024
- Part D point of sale (median)$36.92per unitnegotiated price across 129 plans — before rebates · Apr 1, 2026
- Federal contracts pay (FSS)$4,504.19per package of 180MLJazz Pharmaceuticals, Inc. · Jan 1, 2026
- List price (WAC, as filed)$7,050.00per packageJazz Pharmaceuticals, Inc. · Jan 15, 2026
Medicare Part D
All Part D pricing →ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$36.92per unit
middle half $36.92–$39.78 · 129 plans · Apr 1, 2026
Est. net of rebatesⓘ
$22.15–$27.69
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
2%of plans cover it
tier 5 · prior auth 100% · step therapy 0% · qty limit 30%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$6,590.00
Reported to Texas DSHS · 2026 annual filing · Jazz Pharmaceuticals, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$150.8M
9,337 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 4 of 6 public criteria. Why that matters →
- Part D specialty tier · median tier 5 across plans
- Costs ≥ $950/fill · avg $17,100.22 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Xywav and Xyrem
Regulatory
- Application
- NDA212690
- TE code
- —
- Approval date
- Jul 21, 2020
- Patents / exclusivity
- 22 patents, 3 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | ODE-369 | Aug 12, 2028 |
| exclusivity | PED | Jan 21, 2028 |
| exclusivity | ODE-361 | Jul 21, 2027 |
| patent | 12138233 | Feb 22, 2041 |
| patent | 12582622 | Feb 22, 2041 |
| patent | 11426373 | Sep 19, 2037 |
| patent | 9050302*PED | Sep 15, 2033 |
| patent | 8772306*PED | Sep 15, 2033 |
| patent | 9486426*PED | Sep 15, 2033 |
| patent | 10864181*PED | Sep 15, 2033 |
| patent | 10213400*PED | Sep 15, 2033 |
| patent | 11253494*PED | Sep 15, 2033 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of calcium, magnesium, potassium, and sodium oxybates (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Jazz Pharmaceuticals, Inc. | SODIUM OXYBATE .5 g/mL; CALCIUM OXYBATE .5 g/mL; POTASSIUM OXYBATE .5 g/mL; MAGNESIUM OXYBATE .5 g/mL | Jul 22, 2026 | Sep 2, 2026 |
| Jazz Pharmaceuticals, Inc. | CALCIUM OXYBATE .5 g/mL; MAGNESIUM OXYBATE .5 g/mL; POTASSIUM OXYBATE .5 g/mL; SODIUM OXYBATE .5 g/mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Xywav — NDC 68727-0150-01," retrieved September 3, 2026, https://drugdashboards.com/drug/68727015001.
Free to cite with attribution — see how the data is put together.